CN Stock MarketDetailed Quotes

600750 Jiangzhong Pharmaceutical

Watchlist
  • 22.35
  • +0.17+0.77%
Market Closed Mar 21 15:00 CST
14.06BMarket Cap17.84P/E (TTM)

Jiangzhong Pharmaceutical Key Stats

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
Total operating revenue
-2.59%4.44B
-8.19%2.97B
-8.02%2.17B
-8.74%1.23B
17.19%4.55B
12.61%3.24B
24.26%2.36B
44.50%1.34B
35.19%3.89B
48.33%2.87B
Operating revenue
-2.59%4.44B
-8.19%2.97B
-8.02%2.17B
-8.74%1.23B
17.19%4.55B
12.61%3.24B
24.26%2.36B
44.50%1.34B
35.19%3.89B
48.33%2.87B
Other operating revenue
20.15%31.51M
----
-19.09%17.62M
----
-33.75%26.23M
----
-49.24%21.77M
----
121.34%39.58M
----
Total operating cost
-5.01%3.46B
-13.07%2.22B
-13.43%1.6B
-15.24%899.42M
12.81%3.64B
10.43%2.55B
26.36%1.84B
47.03%1.06B
38.08%3.23B
59.61%2.31B
Operating cost
-1.22%1.62B
-11.23%960.83M
-13.77%672.58M
-13.08%383.29M
18.32%1.64B
12.57%1.08B
22.83%779.95M
49.36%440.96M
35.07%1.38B
46.96%961.56M
Operating tax surcharges
1.24%64.29M
-2.17%45.31M
1.66%32.37M
1.58%17.71M
6.29%63.51M
1.15%46.31M
0.07%31.85M
15.32%17.43M
13.93%59.75M
15.66%45.78M
Operating expense
-8.89%1.49B
-15.48%1.06B
-15.17%780.76M
-16.14%451.23M
8.83%1.64B
11.07%1.25B
34.88%920.44M
52.34%538.07M
46.17%1.51B
78.13%1.12B
Administration expense
3.60%229M
-5.74%136.35M
-6.80%86.54M
-20.98%39.86M
7.40%221.03M
14.50%144.65M
17.42%92.86M
32.51%50.45M
24.70%205.8M
30.95%126.33M
Financial expense
-23.62%-75.32M
-37.09%-59.55M
-53.50%-40.82M
-71.23%-21.29M
-120.83%-60.93M
-97.51%-43.44M
-108.35%-26.59M
-57.37%-12.43M
-23.07%-27.59M
3.43%-21.99M
-Interest expense (Financial expense)
-75.56%1.71M
-93.49%251.88K
-93.24%231.23K
-98.96%16.8K
59.38%6.98M
140.90%3.87M
149.32%3.42M
2,824.40%1.62M
26.51%4.38M
10,874.70%1.61M
-Interest Income (Financial expense)
-12.64%-77.48M
-25.23%-60.13M
-36.59%-41.27M
-51.29%-21.41M
-110.81%-68.79M
-99.13%-48.01M
-110.81%-30.21M
-75.83%-14.15M
-24.08%-32.63M
-4.94%-24.11M
Research and development
-7.77%130.43M
9.91%77.86M
42.20%65.05M
7.41%28.62M
41.46%141.42M
-2.80%70.84M
3.88%45.75M
-4.76%26.64M
13.83%99.97M
52.60%72.88M
Credit Impairment Loss
5,470.58%14.47M
217.78%23.03M
360.28%23.86M
658.32%11.4M
101.85%259.68K
10.71%7.25M
18.73%5.18M
-56.14%1.5M
-74.70%-14.05M
616.53%6.55M
Asset Impairment Loss
-65.34%-16.07M
-162,465.75%-8.04M
-153,703.37%-7.61M
---8.22M
-8,541.20%-9.72M
-99.80%4.95K
-99.88%4.95K
----
91.85%-112.5K
2,002.27%2.54M
Other net revenue
1,539.03%54.15M
16.20%50.84M
-6.72%40.14M
-60.14%7.23M
-96.45%3.3M
-41.52%43.76M
-16.19%43.03M
-10.58%18.14M
2.08%93.11M
13.93%74.82M
Fair value change income
76.75%-8.63M
-85.20%844.29K
-95.09%844.28K
-91.35%620.29K
-164.99%-37.11M
-85.18%5.7M
-23.04%17.21M
-22.10%7.17M
6.50%57.1M
25.15%38.49M
Invest income
3.70%-2.83M
-373.71%-2.61M
-807.10%-1.44M
55.27%-156.92K
-167.23%-2.94M
-81.43%953.69K
-103.82%-158.59K
-129.50%-350.86K
284.88%4.37M
2,688.24%5.14M
-Including: Investment income associates
66.75%-976.9K
-242.61%-1.36M
-198.94%-474.1K
41.35%-205.78K
-257.74%-2.94M
72.57%953.69K
-134.83%-158.59K
-129.23%-350.86K
72.82%-821.16K
216.85%552.65K
Asset deal income
50.80%1.84M
-5,557.23%-292.78K
1,334.57%70.26K
7,296.53%43.74K
1,008.60%1.22M
-89.21%5.36K
-90.67%4.9K
117.77%591.41
-114.87%-134.14K
-94.50%49.7K
Other revenue
26.72%65.38M
27.04%37.91M
17.41%24.41M
-63.92%3.54M
12.32%51.59M
35.21%29.84M
28.87%20.79M
258.01%9.82M
-5.25%45.93M
-33.22%22.07M
Operating profit
12.65%1.03B
10.30%806.85M
9.88%616.18M
11.03%335.22M
21.97%912.81M
14.17%731.52M
13.82%560.78M
31.66%301.91M
19.56%748.41M
14.99%640.71M
Add:Non operating Income
-15.22%8.21M
-23.73%6.03M
-10.96%4.82M
-76.30%1.2M
32.37%9.69M
226.25%7.91M
306.72%5.42M
645.58%5.05M
237.74%7.32M
65.20%2.42M
Less:Non operating expense
70.81%10.9M
291.82%5.32M
29.05%1.16M
-28.85%356.7K
161.02%6.38M
29.68%1.36M
19.53%902.48K
289.21%501.3K
-51.25%2.44M
-56.43%1.05M
Total profit
11.95%1.03B
9.42%807.56M
9.65%619.84M
9.66%336.06M
21.62%916.12M
14.95%738.07M
14.61%565.3M
33.32%306.46M
20.88%753.28M
15.43%642.08M
Less:Income tax cost
27.88%165.11M
11.87%123.67M
7.99%95.42M
10.25%51.51M
20.79%129.11M
6.60%110.55M
9.92%88.36M
28.83%46.72M
15.94%106.89M
15.44%103.7M
Net profit
9.34%860.51M
8.98%683.89M
9.96%524.42M
9.55%284.55M
21.75%787.01M
16.56%627.52M
15.52%476.93M
34.17%259.74M
21.74%646.39M
15.42%538.38M
Net profit from continuing operation
9.34%860.51M
8.98%683.89M
9.96%524.42M
9.55%284.55M
21.75%787.01M
16.56%627.52M
15.52%476.93M
34.17%259.74M
21.74%646.39M
15.42%538.38M
Less:Minority Profit
5.82%72.31M
40.80%49.55M
31.44%35.67M
3.38%17.77M
41.92%68.34M
5.23%35.19M
31.92%27.13M
73.60%17.18M
90.61%48.15M
128.98%33.44M
Net profit of parent company owners
9.67%788.19M
7.09%634.34M
8.66%488.75M
9.99%266.78M
20.13%718.67M
17.31%592.33M
14.66%449.8M
32.04%242.56M
18.30%598.24M
11.75%504.94M
Earning per share
Basic earning per share
9.65%1.25
7.45%1.01
8.33%0.78
10.26%0.43
20.00%1.14
17.50%0.94
16.13%0.72
34.48%0.39
18.75%0.95
11.11%0.8
Diluted earning per share
9.65%1.25
7.45%1.01
8.33%0.78
10.26%0.43
20.00%1.14
17.50%0.94
16.13%0.72
34.48%0.39
18.75%0.95
11.11%0.8
Other composite income
Total composite income
9.34%860.51M
8.98%683.89M
9.96%524.42M
9.55%284.55M
21.75%787.01M
16.56%627.52M
15.52%476.93M
34.17%259.74M
21.74%646.39M
15.42%538.38M
Total composite income of parent company owners
9.67%788.19M
7.09%634.34M
8.66%488.75M
9.99%266.78M
20.13%718.67M
17.31%592.33M
14.66%449.8M
32.04%242.56M
18.30%598.24M
11.75%504.94M
Total composite income of minority owners
5.82%72.31M
40.80%49.55M
31.44%35.67M
3.38%17.77M
41.92%68.34M
5.23%35.19M
31.92%27.13M
73.60%17.18M
90.61%48.15M
128.98%33.44M
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
Unqualified opinion
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
Auditor
KPMG Huazhen Certified Public Accountants (Special General Partnership)
--
--
--
KPMG Huazhen Certified Public Accountants (Special General Partnership)
--
--
--
Ernst & Young Huaming Certified Public Accountants (Special General Partnership)
--
(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022
Total operating revenue -2.59%4.44B-8.19%2.97B-8.02%2.17B-8.74%1.23B17.19%4.55B12.61%3.24B24.26%2.36B44.50%1.34B35.19%3.89B48.33%2.87B
Operating revenue -2.59%4.44B-8.19%2.97B-8.02%2.17B-8.74%1.23B17.19%4.55B12.61%3.24B24.26%2.36B44.50%1.34B35.19%3.89B48.33%2.87B
Other operating revenue 20.15%31.51M-----19.09%17.62M-----33.75%26.23M-----49.24%21.77M----121.34%39.58M----
Total operating cost -5.01%3.46B-13.07%2.22B-13.43%1.6B-15.24%899.42M12.81%3.64B10.43%2.55B26.36%1.84B47.03%1.06B38.08%3.23B59.61%2.31B
Operating cost -1.22%1.62B-11.23%960.83M-13.77%672.58M-13.08%383.29M18.32%1.64B12.57%1.08B22.83%779.95M49.36%440.96M35.07%1.38B46.96%961.56M
Operating tax surcharges 1.24%64.29M-2.17%45.31M1.66%32.37M1.58%17.71M6.29%63.51M1.15%46.31M0.07%31.85M15.32%17.43M13.93%59.75M15.66%45.78M
Operating expense -8.89%1.49B-15.48%1.06B-15.17%780.76M-16.14%451.23M8.83%1.64B11.07%1.25B34.88%920.44M52.34%538.07M46.17%1.51B78.13%1.12B
Administration expense 3.60%229M-5.74%136.35M-6.80%86.54M-20.98%39.86M7.40%221.03M14.50%144.65M17.42%92.86M32.51%50.45M24.70%205.8M30.95%126.33M
Financial expense -23.62%-75.32M-37.09%-59.55M-53.50%-40.82M-71.23%-21.29M-120.83%-60.93M-97.51%-43.44M-108.35%-26.59M-57.37%-12.43M-23.07%-27.59M3.43%-21.99M
-Interest expense (Financial expense) -75.56%1.71M-93.49%251.88K-93.24%231.23K-98.96%16.8K59.38%6.98M140.90%3.87M149.32%3.42M2,824.40%1.62M26.51%4.38M10,874.70%1.61M
-Interest Income (Financial expense) -12.64%-77.48M-25.23%-60.13M-36.59%-41.27M-51.29%-21.41M-110.81%-68.79M-99.13%-48.01M-110.81%-30.21M-75.83%-14.15M-24.08%-32.63M-4.94%-24.11M
Research and development -7.77%130.43M9.91%77.86M42.20%65.05M7.41%28.62M41.46%141.42M-2.80%70.84M3.88%45.75M-4.76%26.64M13.83%99.97M52.60%72.88M
Credit Impairment Loss 5,470.58%14.47M217.78%23.03M360.28%23.86M658.32%11.4M101.85%259.68K10.71%7.25M18.73%5.18M-56.14%1.5M-74.70%-14.05M616.53%6.55M
Asset Impairment Loss -65.34%-16.07M-162,465.75%-8.04M-153,703.37%-7.61M---8.22M-8,541.20%-9.72M-99.80%4.95K-99.88%4.95K----91.85%-112.5K2,002.27%2.54M
Other net revenue 1,539.03%54.15M16.20%50.84M-6.72%40.14M-60.14%7.23M-96.45%3.3M-41.52%43.76M-16.19%43.03M-10.58%18.14M2.08%93.11M13.93%74.82M
Fair value change income 76.75%-8.63M-85.20%844.29K-95.09%844.28K-91.35%620.29K-164.99%-37.11M-85.18%5.7M-23.04%17.21M-22.10%7.17M6.50%57.1M25.15%38.49M
Invest income 3.70%-2.83M-373.71%-2.61M-807.10%-1.44M55.27%-156.92K-167.23%-2.94M-81.43%953.69K-103.82%-158.59K-129.50%-350.86K284.88%4.37M2,688.24%5.14M
-Including: Investment income associates 66.75%-976.9K-242.61%-1.36M-198.94%-474.1K41.35%-205.78K-257.74%-2.94M72.57%953.69K-134.83%-158.59K-129.23%-350.86K72.82%-821.16K216.85%552.65K
Asset deal income 50.80%1.84M-5,557.23%-292.78K1,334.57%70.26K7,296.53%43.74K1,008.60%1.22M-89.21%5.36K-90.67%4.9K117.77%591.41-114.87%-134.14K-94.50%49.7K
Other revenue 26.72%65.38M27.04%37.91M17.41%24.41M-63.92%3.54M12.32%51.59M35.21%29.84M28.87%20.79M258.01%9.82M-5.25%45.93M-33.22%22.07M
Operating profit 12.65%1.03B10.30%806.85M9.88%616.18M11.03%335.22M21.97%912.81M14.17%731.52M13.82%560.78M31.66%301.91M19.56%748.41M14.99%640.71M
Add:Non operating Income -15.22%8.21M-23.73%6.03M-10.96%4.82M-76.30%1.2M32.37%9.69M226.25%7.91M306.72%5.42M645.58%5.05M237.74%7.32M65.20%2.42M
Less:Non operating expense 70.81%10.9M291.82%5.32M29.05%1.16M-28.85%356.7K161.02%6.38M29.68%1.36M19.53%902.48K289.21%501.3K-51.25%2.44M-56.43%1.05M
Total profit 11.95%1.03B9.42%807.56M9.65%619.84M9.66%336.06M21.62%916.12M14.95%738.07M14.61%565.3M33.32%306.46M20.88%753.28M15.43%642.08M
Less:Income tax cost 27.88%165.11M11.87%123.67M7.99%95.42M10.25%51.51M20.79%129.11M6.60%110.55M9.92%88.36M28.83%46.72M15.94%106.89M15.44%103.7M
Net profit 9.34%860.51M8.98%683.89M9.96%524.42M9.55%284.55M21.75%787.01M16.56%627.52M15.52%476.93M34.17%259.74M21.74%646.39M15.42%538.38M
Net profit from continuing operation 9.34%860.51M8.98%683.89M9.96%524.42M9.55%284.55M21.75%787.01M16.56%627.52M15.52%476.93M34.17%259.74M21.74%646.39M15.42%538.38M
Less:Minority Profit 5.82%72.31M40.80%49.55M31.44%35.67M3.38%17.77M41.92%68.34M5.23%35.19M31.92%27.13M73.60%17.18M90.61%48.15M128.98%33.44M
Net profit of parent company owners 9.67%788.19M7.09%634.34M8.66%488.75M9.99%266.78M20.13%718.67M17.31%592.33M14.66%449.8M32.04%242.56M18.30%598.24M11.75%504.94M
Earning per share
Basic earning per share 9.65%1.257.45%1.018.33%0.7810.26%0.4320.00%1.1417.50%0.9416.13%0.7234.48%0.3918.75%0.9511.11%0.8
Diluted earning per share 9.65%1.257.45%1.018.33%0.7810.26%0.4320.00%1.1417.50%0.9416.13%0.7234.48%0.3918.75%0.9511.11%0.8
Other composite income
Total composite income 9.34%860.51M8.98%683.89M9.96%524.42M9.55%284.55M21.75%787.01M16.56%627.52M15.52%476.93M34.17%259.74M21.74%646.39M15.42%538.38M
Total composite income of parent company owners 9.67%788.19M7.09%634.34M8.66%488.75M9.99%266.78M20.13%718.67M17.31%592.33M14.66%449.8M32.04%242.56M18.30%598.24M11.75%504.94M
Total composite income of minority owners 5.82%72.31M40.80%49.55M31.44%35.67M3.38%17.77M41.92%68.34M5.23%35.19M31.92%27.13M73.60%17.18M90.61%48.15M128.98%33.44M
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions Unqualified opinion------Unqualified opinion------Unqualified opinion--
Auditor KPMG Huazhen Certified Public Accountants (Special General Partnership)------KPMG Huazhen Certified Public Accountants (Special General Partnership)------Ernst & Young Huaming Certified Public Accountants (Special General Partnership)--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.